Your browser doesn't support javascript.
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 47
Filtrar
Mais filtros










Intervalo de ano de publicação
1.
BMC Infect Dis ; 20(1): 232, 2020 Mar 19.
Artigo em Inglês | MEDLINE | ID: mdl-32188404

RESUMO

BACKGROUND: The most common infection in patients positive for anti-interferon-gamma autoantibodies (anti-IFN-γ AAbs) is disseminated nontuberculous mycobacterial (dNTM) infection. Here, we report a rare case of triple infection caused by Cryptococcus, varicella-zoster virus (VZV), and nontuberculous mycobacterium in a patient with anti-IFN-γ AAbs. CASE PRESENTATION: A 53-year-old Thai man presented with a progressively enlarging right cervical mass with low-grade fever and significant weight loss for 4 months. He also developed a lesion at his left index finger. A biopsy of that lesion showed granulomatous inflammation with yeast-like organisms morphologically consistent with cryptococcosis. Serum cryptococcal antigen was positive. Histopathology of a right cervical lymph node revealed chronic granulomatous lymphadenitis, and the lymph node culture grew Mycobacterium abscessus. One month later, he complained of vision loss in his left eye and subsequently developed a group of painful vesicles at the right popliteal area of S1 dermatome. Lumbar puncture was performed and his cerebrospinal fluid was positive for VZV DNA. His blood test for anti-HIV antibody was negative. Anti-IFN-γ AAbs was positive, but test for anti-granulocyte-macrophage colony-stimulating factor autoantibodies (anti-GM-CSF AAbs) was negative. He was treated with amphotericin B plus fluconazole for cryptococcosis; a combination of amikacin, imipenem, azithromycin, and levofloxacin for dNTM infection; and, intravenous acyclovir for disseminated VZV infection. After treatment, our patient's fever and cervical lymphadenopathy were subsided, and his vision and visual acuity were both improved. CONCLUSIONS: This is the first case of triple infection with cryptococcosis, VZV, and dNTM in a patient who tested positive for anti-IFN-γ AAbs and negative for anti-GM-CSF AAbs. This case will increase awareness and heighten suspicion of these infections in patients with the described presentations and clinical characteristics, and this will accelerate diagnosis and treatment.


Assuntos
Criptococose/tratamento farmacológico , Síndromes de Imunodeficiência/complicações , Infecções por Mycobacterium não Tuberculosas/tratamento farmacológico , Aciclovir/uso terapêutico , Anfotericina B/uso terapêutico , Autoanticorpos , Coinfecção , Criptococose/microbiologia , Fluconazol/uso terapêutico , Herpesvirus Humano 3/imunologia , Humanos , Interferon gama/imunologia , Linfadenopatia , Masculino , Pessoa de Meia-Idade , Infecções por Mycobacterium não Tuberculosas/microbiologia , Mycobacterium abscessus , Infecção pelo Vírus da Varicela-Zoster/tratamento farmacológico
2.
BMC Infect Dis ; 20(1): 159, 2020 Feb 19.
Artigo em Inglês | MEDLINE | ID: mdl-32075599

RESUMO

BACKGROUND: Varicella-zoster virus (VZV) infection can be diagnosed clinically once classical rash occurs but the diagnosis is challenging when typical rash is absent. We reported a case of fulminant central nervous system (CNS) VZV infection in a human immunodeficiency virus (HIV)-infected patient without typical VZV-related rash. CNS VZV infection was unexpected identified by metagenomic next-generation sequencing (mNGS). CASE PRESENTATION: A 28-year-old HIV-infected patient presented with neurological symptoms for 3 days. The patient, who was not suspected of VZV infection at admission, quickly progressed to deep coma during the first 24 h of hospitalization. An unbiased mNGS was performed on DNA extract from 300 µL cerebrospinal fluid (CSF) with the BGISEQ-50 platform. The sequencing detection identified 97,248 (out of 38,561,967) sequence reads uniquely aligned to the VZV genome, and these reads covered a high percentage (99.91%) of the VZV. Presence of VZV DNA in CSF was further verified by VZV-specific polymerase chain reaction and Sanger sequencing. Altogether, those results confirmed CNS VZV infection. CONCLUSIONS: This study suggests that mNGS may be a useful diagnostic tool for CNS VZV infection. As mNGS could identify all pathogens directly from CSF sample in a single run, it has the promise of strengthening our ability to diagnose CNS infections in HIV-infected patients.


Assuntos
Viroses do Sistema Nervoso Central/diagnóstico , Infecções por HIV/virologia , Herpesvirus Humano 3/genética , Infecção pelo Vírus da Varicela-Zoster/diagnóstico , Adulto , Viroses do Sistema Nervoso Central/tratamento farmacológico , Viroses do Sistema Nervoso Central/etiologia , Viroses do Sistema Nervoso Central/virologia , Líquido Cefalorraquidiano/virologia , DNA Viral/líquido cefalorraquidiano , Herpesvirus Humano 3/patogenicidade , Sequenciamento de Nucleotídeos em Larga Escala , Humanos , Masculino , Metagenoma , Infecção pelo Vírus da Varicela-Zoster/tratamento farmacológico , Infecção pelo Vírus da Varicela-Zoster/etiologia , Infecção pelo Vírus da Varicela-Zoster/virologia
6.
Gastroenterology ; 157(4): e8-e9, 2019 10.
Artigo em Inglês | MEDLINE | ID: mdl-31476298
8.
BMJ Case Rep ; 12(8)2019 Aug 21.
Artigo em Inglês | MEDLINE | ID: mdl-31439560

RESUMO

This case describes an uncommon presentation of herpes zoster in an adolescent with viral meningitis and concomitant genital shingles. A 15-year-old immunocompetent girl with background of well-controlled Graves' disease presented with 3 days of fever, frontal headache, terminal neck stiffness and photophobia. This was preceded by 4 days of pain and itch over vaginal and anal region. She had one dose of varicella vaccination at 18 months old and developed mild primary varicella infection around 5 years of age. Varicella zoster virus DNA was detected both in cerebrospinal fluid and in vesicles over her right labial majora. While there is no international consensus on the recommended duration of treatment for zoster with neurological complications, she was treated with intravenous acyclovir for 10 days with good clinical response. Her fever, headache and neck stiffness resolved after 2 days and genital lesions resolved after 9 days of antiviral therapy.


Assuntos
Doença de Graves , Herpes Zoster/diagnóstico , Herpesvirus Humano 3/isolamento & purificação , Meningite Viral/diagnóstico , Infecção pelo Vírus da Varicela-Zoster/diagnóstico , Aciclovir/administração & dosagem , Aciclovir/uso terapêutico , Adolescente , Antivirais/administração & dosagem , Antivirais/uso terapêutico , Diagnóstico Diferencial , Feminino , Genitália , Herpes Zoster/complicações , Herpes Zoster/tratamento farmacológico , Humanos , Meningite Viral/complicações , Meningite Viral/tratamento farmacológico , Infecção pelo Vírus da Varicela-Zoster/complicações , Infecção pelo Vírus da Varicela-Zoster/tratamento farmacológico
9.
Brain Behav ; 9(9): e01374, 2019 09.
Artigo em Inglês | MEDLINE | ID: mdl-31342665

RESUMO

INTRODUCTION: Acute disseminated encephalomyelitis (ADEM) is an idiopathic inflammatory demyelinating disorder of the central nervous system (CNS). Early treatment is the key for neurological recovery. METHODS: A case of ADEM associated with varicella-zoster virus infection was presented, in which magnetic resonance imaging (MRI), cerebrospinal fluid (CSF) examinations were included. RESULTS: Magnetic resonance imaging of the brain revealed multiple hyperintense lesions at the subcortical level on fluid-attenuated inversion recovery (FLAIR), and MRI of the spinal cord revealed longitudinally segmented hyperintense lesions at the spinal cord on T2-weighted images. The patient was treated with methylprednisolone and gancyclovir, and had a favorable recovery. Subsequent MRI of the brain and cervical cord showed the previous abnormal hyperintensities had markedly disappeared. CONCLUSION: A rare case of ADEM with longitudinal segmented hyperintense lesions at the spinal cord on T2-weighted images was presented. Excellent response to ADEM treatment with high-dose steroids was reported resulting in a remarkable neurological recovery. A long-term follow-up is needed for prognosis.


Assuntos
Encéfalo/diagnóstico por imagem , Encefalomielite Aguda Disseminada/complicações , Encefalomielite Aguda Disseminada/diagnóstico por imagem , Imagem por Ressonância Magnética/métodos , Medula Espinal/diagnóstico por imagem , Infecção pelo Vírus da Varicela-Zoster/complicações , Adolescente , Anti-Inflamatórios/uso terapêutico , Antivirais/uso terapêutico , Encéfalo/patologia , Encéfalo/virologia , Encefalomielite Aguda Disseminada/líquido cefalorraquidiano , Encefalomielite Aguda Disseminada/tratamento farmacológico , Feminino , Ganciclovir/uso terapêutico , Humanos , Metilprednisolona/uso terapêutico , Neuroimagem/métodos , Medula Espinal/virologia , Resultado do Tratamento , Infecção pelo Vírus da Varicela-Zoster/líquido cefalorraquidiano , Infecção pelo Vírus da Varicela-Zoster/diagnóstico , Infecção pelo Vírus da Varicela-Zoster/tratamento farmacológico
10.
BMC Infect Dis ; 19(1): 625, 2019 Jul 15.
Artigo em Inglês | MEDLINE | ID: mdl-31307420

RESUMO

BACKGROUND: Visceral disseminated varicella zoster virus (VDVZV) infection is a rare disease with a high mortality rate (55%) in immunocompromised patients, but it is not yet widely recognized in the field of nephrology. We report a case of VDVZV contracted during immunosuppressive therapy for membranous nephropathy. CASE PRESENTATION: A 36-year-old woman was diagnosed with membranous nephropathy and was being treated with immunosuppressive therapy consisting of 60 mg/day prednisolone, 150 mg/day mizoribine, and 150 mg/day cyclosporine. Nephrosis eased; therefore, the prednisolone dosage was reduced. However, 50 days after starting immunosuppressive therapy, the patient suddenly developed strong and spontaneous abdominal pain, predominantly in the epigastric area, without muscular guarding or rebound tenderness. Blood data indicated neutrophil-dominant elevated white blood cell count, reduced platelet count, elevated transaminase and lactate dehydrogenase, slightly increased C-reactive protein, and enhanced coagulability. Abdominal computed tomography revealed a mildly increased enhancement around the root of the superior mesenteric artery with no perforation, intestinal obstruction, or thrombosis. The cause of the abdominal pain was unknown, so the patient was carefully monitored and antibiotic agents and opioid analgesics administered. The following day, blisters appeared on the patient's skin, which were diagnosed as varicella. There was a marked increase in the blood concentration of VZV-DNA; therefore, the cause of the abdominal pain was diagnosed as VDVZV. Treatment with acyclovir and immunoglobulin was immediately started, and the immunosuppressive therapy dose reduced. The abdominal pain resolved rapidly, and the patient was discharged 1 week after symptom onset. DISCUSSIONS AND CONCLUSIONS: This patient was VZV-IgG positive, but developed VDVZV due to reinfection. Abdominal pain due to VDVZV precedes the skin rash, which makes it difficult to diagnose before the appearance of the rash, but measuring the VZV-DNA concentration in the blood may be effective. Saving the patient's life requires urgent administration of sufficient doses of acyclovir and reduced immunosuppressive therapy.


Assuntos
Glomerulonefrite Membranosa/diagnóstico , Herpesvirus Humano 3/isolamento & purificação , Infecção pelo Vírus da Varicela-Zoster/diagnóstico , Dor Abdominal/etiologia , Aciclovir/uso terapêutico , Adulto , Antivirais/uso terapêutico , Contagem de Células Sanguíneas , DNA Viral/sangue , Feminino , Glomerulonefrite Membranosa/complicações , Glomerulonefrite Membranosa/tratamento farmacológico , Herpesvirus Humano 3/genética , Humanos , Imunoglobulinas/uso terapêutico , Imunossupressores/efeitos adversos , Imunossupressores/uso terapêutico , Tomografia Computadorizada por Raios X , Infecção pelo Vírus da Varicela-Zoster/complicações , Infecção pelo Vírus da Varicela-Zoster/tratamento farmacológico
11.
Int J Infect Dis ; 85: 70-73, 2019 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-31132473

RESUMO

Varicella zoster virus (VZV) pneumonia is associated with significant mortality, especially in the immunocompromised host. VZV-specific immunoglobulins (VZIG) are currently used as post-exposure prophylaxis for at-risk patients, but not as adjunctive therapy. A novel case of VZV pneumonia in an immunocompromised patient, treated successfully with intravenous VZIG in combination with acyclovir, is reported here.


Assuntos
Adjuvantes Imunológicos/uso terapêutico , Anticorpos Antivirais/uso terapêutico , Herpesvirus Humano 3/imunologia , Pneumonia Viral/tratamento farmacológico , Infecção pelo Vírus da Varicela-Zoster/tratamento farmacológico , Aciclovir/uso terapêutico , Adjuvantes Imunológicos/administração & dosagem , Administração Intravenosa , Adulto , Anticorpos Antivirais/administração & dosagem , Antivirais/uso terapêutico , Humanos , Hospedeiro Imunocomprometido , Masculino
12.
Intern Med ; 58(14): 2101-2105, 2019 Jul 15.
Artigo em Inglês | MEDLINE | ID: mdl-30918176

RESUMO

A 43-year-old man with malignant lymphoma who had been treated with the cyclosphamide, vincrstine, procarbazine, and prednisolone (C-MOPP) regimen was admitted to our hospital with skin eruption. He was diagnosed to have varicella, and treatment with acyclovir and immune globulin was started. Chest computed tomography revealed multiple nodules in the both lung fields. Diagnostic thoracoscopic lung biopsy specimens revealed granuloma formation, and polymerase chain reaction testing revealed the presence of varicella-zoster virus DNA in the granulomatous tissue. It was unusual for the lung nodule in varicella pneumonia to increase in size over time in a patient who had undergone antiviral therapy, while also demonstrating multiple granulomas.


Assuntos
Granuloma/genética , Granuloma/virologia , Pneumonia/patologia , Pneumonia/virologia , Infecção pelo Vírus da Varicela-Zoster/complicações , Infecção pelo Vírus da Varicela-Zoster/tratamento farmacológico , Infecção pelo Vírus da Varicela-Zoster/genética , Aciclovir/uso terapêutico , Adulto , Antivirais/uso terapêutico , Ciclofosfamida/uso terapêutico , DNA Viral/isolamento & purificação , Humanos , Masculino , Pneumonia/etiologia , Reação em Cadeia da Polimerase , Prednisolona/uso terapêutico , Procarbazina/uso terapêutico , Tomografia Computadorizada por Raios X , Resultado do Tratamento , Infecção pelo Vírus da Varicela-Zoster/diagnóstico , Vincristina/uso terapêutico
13.
Ocul Immunol Inflamm ; 27(8): 1270-1279, 2019.
Artigo em Inglês | MEDLINE | ID: mdl-30252558

RESUMO

Objective: To explore the clinical characteristics and in vivo confocal microscopic (IVCM) findings of varicella zoster virus (VZV)-related corneal endotheliitis.Methods: Retrospectively reviewed 20 eyes with corneal edema which were diagnosed by real-time polymerase chain reaction.Results: one had VZV infection. Three had epithelial lesions. Six had mydriasis. Four had loss of iris pigment. Keratic precipitates (KPs) were mixed. Subbasal nerves had disappeared in 12 eyes. Langerhans cells were observed in seven eyes. The deviations in endothelial cell layers consisted of guttate (n = 1), enlarged intercellular gaps (n = 11), infiltration of inflammatory cells (n = 8), loss of defined cell boundaries (n = 1) and anomalous nucleus (n = 9). The shape of KPs in IVCM included type I (n = 6), type III (n = 3) and type IV (n = 4).Conclusion: VZV-related corneal endotheliitis is remarkably difficult to detect clinically. Most cases have no typical skin lesions. The typical clinical feature is that of segmental iris atrophy and mixed KPs.


Assuntos
DNA Viral/análise , Epitélio Posterior/patologia , Infecções Oculares Virais/diagnóstico , Herpesvirus Humano 3/genética , Ceratite/diagnóstico , Microscopia Confocal/métodos , Infecção pelo Vírus da Varicela-Zoster/diagnóstico , Adolescente , Adulto , Idoso , Idoso de 80 Anos ou mais , Antivirais/uso terapêutico , Humor Aquoso/virologia , Criança , Pré-Escolar , Infecções Oculares Virais/tratamento farmacológico , Infecções Oculares Virais/virologia , Feminino , Seguimentos , Ganciclovir/uso terapêutico , Humanos , Ceratite/tratamento farmacológico , Ceratite/virologia , Masculino , Pessoa de Meia-Idade , Estudos Retrospectivos , Tomografia de Coerência Óptica/métodos , Infecção pelo Vírus da Varicela-Zoster/tratamento farmacológico , Infecção pelo Vírus da Varicela-Zoster/virologia , Adulto Jovem
14.
J Stroke Cerebrovasc Dis ; 28(2): 338-343, 2019 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-30392831

RESUMO

BACKGROUND: Limited data are available regarding the characteristics and prognosis of patients with stroke due to varicella zoster virus (VZV) vasculopathy. METHODS: We studied 4 patients (2 men and 2 women; age, 38-63 years) from a single center who developed acute ischemic stroke due to VZV vasculopathy. The virological diagnosis was confirmed by detecting VZV DNA and/or the IgG antibody to VZV in the cerebrospinal fluid. RESULTS: Three patients were taking immunosuppressive agents, including prednisolone and/or methotrexate, at baseline. Each patient had a characteristic skin rash prior to stroke, with the interval from rash to stroke onset ranging from 13 to 122 days. Two patients experienced antecedent cranial nerve palsies; one had the third, seventh, ninth, and 10th nerve palsies and the other had the fourth nerve palsy before stroke. Cerebral infarctions were located in the anterior circulation lesion (n = 1), in the posterior circulation lesion (n = 2), and in both lesions (n = 1). Intracranial arterial stenosis was only identified in one patient on magnetic resonance angiography. A high plasma d-dimer level was detected in 1 patient, whereas high ß-thromboglobulin and platelet factor 4 levels were detected in 2 patients. As a result of combined therapies with acyclovir, steroid, and antithrombotic agents, neurological symptoms markedly improved in 3 patients, whereas 1 patient was left with moderate hemiplegia. CONCLUSIONS: Cranial nerve palsies may be prodromal symptoms of VZV-associated stroke. Increased levels of thrombotic markers may support the use of antithrombotic agents, although the benefit of combined treatment should be determined through larger studies.


Assuntos
Isquemia Encefálica/virologia , Herpesvirus Humano 3/patogenicidade , Acidente Vascular Cerebral/virologia , Infecção pelo Vírus da Varicela-Zoster/virologia , Aciclovir/uso terapêutico , Adulto , Antivirais/uso terapêutico , Isquemia Encefálica/diagnóstico por imagem , Isquemia Encefálica/tratamento farmacológico , Doenças dos Nervos Cranianos/virologia , Imagem de Difusão por Ressonância Magnética , Feminino , Fibrinolíticos/uso terapêutico , Herpesvirus Humano 3/efeitos dos fármacos , Humanos , Angiografia por Ressonância Magnética , Masculino , Pessoa de Meia-Idade , Estudos Retrospectivos , Esteroides/uso terapêutico , Acidente Vascular Cerebral/diagnóstico por imagem , Acidente Vascular Cerebral/tratamento farmacológico , Resultado do Tratamento , Infecção pelo Vírus da Varicela-Zoster/complicações , Infecção pelo Vírus da Varicela-Zoster/diagnóstico , Infecção pelo Vírus da Varicela-Zoster/tratamento farmacológico
16.
Pharmazie ; 73(12): 733-736, 2018 12 01.
Artigo em Inglês | MEDLINE | ID: mdl-30522559

RESUMO

Propolis is a generic name for a biological substance produced by bees used for multiple purposes in folk medicine. Propolis special extract GH 2002 is crude propolis highly purified by a special procedure and freed from the accompanying substances like pollen, wax, resins. The cytotoxic and antiherpetic effect of propolis extracts against Varicella zoster virus (VZV) was analysed in cell culture, and revealed a moderate cytotoxicity on lung fibroblasts with a CC50 of 380 µg/ml. The 50 % inhibitory concentration (IC50) of GH 2002 propolis extract for VZV plaque formation was determined at 64 µg/ml. The propolis extract exhibited high levels of antiviral activity against VZV in viral suspension tests, infectivity was significantly reduced by 93.9 % and a direct concentration-dependent antiviral activity could be demonstrated. In order to determine the mode of virus suppression by propolis, the extract was added at different times during the viral infection cycle. Addition of propolis to uninfected cells (pretreatment cells) prior to infection or to infected cells (replication) during intracellular replication had no or only minor effect on virus multiplication. However, propolis exhibited high anti-VZV activity when viruses were pretreated with propolis prior to infection thus indicating an unspecific interaction between the virus and propolis. The antiviral activity is comparable to acyclovir.


Assuntos
Antivirais/farmacologia , Herpesvirus Humano 3/efeitos dos fármacos , Própole/farmacologia , Infecção pelo Vírus da Varicela-Zoster/tratamento farmacológico , Aciclovir/farmacologia , Animais , Antivirais/administração & dosagem , Abelhas , Linhagem Celular , Humanos , Concentração Inibidora 50 , Medicina Tradicional , Própole/administração & dosagem , Infecção pelo Vírus da Varicela-Zoster/virologia , Replicação Viral/efeitos dos fármacos
17.
Viruses ; 10(11)2018 11 02.
Artigo em Inglês | MEDLINE | ID: mdl-30400213

RESUMO

Varicella-zoster virus (VZV) is a pathogenic human herpes virus that causes varicella (chickenpox) as a primary infection, following which it becomes latent in peripheral ganglia. Decades later, the virus may reactivate either spontaneously or after a number of triggering factors to cause herpes zoster (shingles). Varicella and its complications are more severe in the immunosuppressed. The most frequent and important complication of VZV reactivation is postherpetic neuralgia, the cause of which is unknown and for which treatment is usually ineffective. Reactivation of VZV may also cause a wide variety of neurological syndromes, the most significant of which is a vasculitis, which is treated with corticosteroids and the antiviral drug acyclovir. Other VZV reactivation complications include an encephalitis, segmental motor weakness and myelopathy, cranial neuropathies, Guillain⁻Barré syndrome, enteric features, and zoster sine herpete, in which the viral reactivation occurs in the absence of the characteristic dermatomally distributed vesicular rash of herpes zoster. There has also been a recent association of VZV with giant cell arteritis and this interesting finding needs further corroboration. Vaccination is now available for the prevention of both varicella in children and herpes zoster in older individuals.


Assuntos
Herpesvirus Humano 3/fisiologia , Infecção pelo Vírus da Varicela-Zoster/diagnóstico , Infecção pelo Vírus da Varicela-Zoster/virologia , Síndrome de Guillain-Barré/etiologia , Humanos , Enteropatias/etiologia , Neuralgia Pós-Herpética/etiologia , Infecção pelo Vírus da Varicela-Zoster/complicações , Infecção pelo Vírus da Varicela-Zoster/tratamento farmacológico , Vacinas Virais/imunologia
19.
Biochem Pharmacol ; 158: 201-206, 2018 12.
Artigo em Inglês | MEDLINE | ID: mdl-30365949

RESUMO

Existing treatments have limited efficacy against severe infection associated with herpes simplex virus (HSV) and herpes zoster virus (VZV), particularly in immunocompromized patients and those with multidermatomal infection. This issue, along with issues regarding drug resistance, support the need for improved therapeutic options. To investigate the antiviral effect of amenamevir, a VZV and HSV helicase-primase inhibitor, in severe infection conditions, mouse models of severe HSV-1 infection were developed by immunosuppression or multidermatomal infection. Mice with cyclosporin-induced immunosuppression and HSV-1 infection via inoculation of a dorsolateral area of skin were orally treated with amenamevir (10-100 mg/kg/day) for different durations (2-5 days). Immunosuppressed mice maintained high skin HSV-1 titers in the absence of treatment. Amenamevir successfully reduced HSV-1 titers at all tested doses in immunosuppressed mice, but required a longer treatment period to avoid a rebound in viral titers due to immunosuppression. To compare the efficacy of amenamevir and valacyclovir, a murine model of multidermatomal HSV-1 infection was generated by scarifying the dorsolateral area of skin in a line and inoculating broadly with HSV-1. The mice were treated with amenamevir or valacyclovir starting on Day 3, 4, or 5 post-infection for 5 days. Although both drugs similarly reduced disease scores when treatment was started on Day 3, amenamevir also reduced disease severity when treatment was initiated on Day 4, whereas valacyclovir did not. Amenamevir was not affected by the host's immune status in terms of effective oral doses and was more efficacious in treating severe cutaneous infection even when treatment initiation was delayed.


Assuntos
Antivirais/uso terapêutico , DNA Helicases/antagonistas & inibidores , DNA Primase/antagonistas & inibidores , Modelos Animais de Doenças , Oxidiazóis/uso terapêutico , Índice de Gravidade de Doença , Infecção pelo Vírus da Varicela-Zoster/tratamento farmacológico , Proteínas Virais/antagonistas & inibidores , Animais , Antivirais/farmacologia , Chlorocebus aethiops , DNA Helicases/metabolismo , DNA Primase/metabolismo , Feminino , Herpesvirus Humano 1/efeitos dos fármacos , Herpesvirus Humano 1/metabolismo , Camundongos , Oxidiazóis/farmacologia , Resultado do Tratamento , Infecção pelo Vírus da Varicela-Zoster/metabolismo , Células Vero , Proteínas Virais/metabolismo
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA